For patients with extensive-stage small cell lung cancer (ES-SCLC)

The trial may last several months after a maximum 4-week screening period. If you qualify and enroll in the trial, there will be a treatment period, followed by check-ins every 12 weeks. During the informed consent process before enrolling, the research team will answer any further questions about the time required.

EVOKE-SCLC-04 will be conducted globally. When you take the pre-screener, we will use your zip code to locate a trial site in your area.

Yes, the EVOKE-SCLC-04 study will include people of various backgrounds, especially those most affected by ES-SCLC. The goal is for the study population to match the racial and ethnic prevalence of ES-SCLC in the US.

If you do not meet the trial criteria to participate, the onsite study team may provide recommendations for the next steps.

As with all medical records, participant privacy and confidentiality in trials are protected by law. Once the consent form is signed, you will be given a trial code. Your trial records will not include your name or personal identity but will identify you with a trial code. This code can only be tracked back to you via a code key which is held by the responsible physician. Your name or personal identity will never be disclosed.

Gilead Sciences is conducting the EVOKE-SCLC-04 clinical trial. Gilead Sciences is a global biopharmaceutical company that is headquartered in Foster City, California.

Yes, participation is voluntary and you may withdraw from a clinical trial at any time.

Your written informed consent is required before being enrolled in EVOKE-SCLC-04. This means you have been provided with all relevant information about the study design, how you will participate, your right to withdraw at any time, study alternatives, your personal data protection and the associated risks and benefits, and have had the opportunity to ask any questions and agree to participate. Informed consent is designed to protect your safety and privacy.

Participants are always welcome to visit their usual healthcare providers during a trial. Sometimes, it is important for healthcare providers to collaborate with the research team to ensure success.

There are a wide variety of professionals involved with any clinical trial, all of whom are vital to ensuring safety and success. The principal investigator, or PI, leads the trial and directs the team of doctors, nurses, and other healthcare workers. The clinical trial coordinator manages day-to-day activities and is the main contact for participants. Many clinical trials also have an independent Data and Safety Monitoring Board (DSMB) who periodically reviews data to ensure participant safety, and sometimes effectiveness.

Clinical trials answer questions about how well a treatment or therapy works and/or how safe it is by monitoring its effect on people (often through bloodwork and other tests, as well as checking for symptoms and side effects). The people in clinical trials are called clinical trial participants and are volunteers who may be healthy or have a specific illness or condition.

Clinical trials are used to determine the safety data and effectiveness of an investigational treatment. The treatment can be a drug, vaccine, medical device, medical procedure, and/or behavioral intervention. Before treatments can be used by the general public, they must undergo a series of clinical trials, called phases, and be approved by regulatory agencies (such as the FDA in the United States and the European Medicines Agency [EMA] in Europe).

After your participation ends, the study may continue for months or years. Once final results from all participants are compiled and analyzed, they are often published publicly. Clinical study report (CSR) synopses and plain language summaries (PLSs) may be made available for certain studies. Check with your clinical trial site or send an email to [email protected] to learn more.